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Abstract
Helicobacter pylori  (H. pylori ) affects nearly half of the 
world’s population and, thus, is one of the most fre-
quent and persistent bacterial infections worldwide. H. 
pylori  is associated with peptic ulcer disease, gastric 
ulcers, mucosa-associated lymphoid tissue lymphoma, 
and gastric cancer. Various diagnostic methods exist 
to detect infection, and the choice of one method or 
another depends on several factors, such as accessibil-
ity, advantages and disadvantages of each method, 
cost, and the age of patients. Once H. pylori  infection 
is diagnosed, the clinician decides whether treatment is 
necessity, according to the patient’s clinical condition. 
Typically, eradication of H. pylori  is recommended for 
treatment and prevention of the infection. Cure rates 
with the standard triple therapy are acceptable, and ef-
fective quadruple therapies, sequential therapies, and 
concomitant therapies have been introduced as key 
alternatives to treat H. pylori  infection. In this work, we 
review the main diagnostic methods used to identify 
H. pylori  infection and to confirm eradication of infec-
tion. In addition, key factors related to treatment are 
reviewed.
© 2014 Baishideng Publishing Group Co., Limited. All rights 
reserved.
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Core tip: This review focuses on diagnostic methods 
used to detect Helicobacter pylori  (H. pylori ) infection 
before and after eradication and on treatment regimens 
for H. pylori  eradication. In this review, we emphasize 
the different regimens recommended in relation to dif-
ferences in antibiotic resistance. Additionally, we review 
a test-and-treat strategy for and effective quadruple 
therapies, such as sequential, concomitant, and hybrid 
therapies. Furthermore, we review the use of probiot-
ics as an additive to help increase H. pylori  eradication 
rates. 
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sponsible for the most frequent and persistent bacterial 
infection worldwide. H. pylori infection affects nearly 
half  of  the world’s population. In developing countries, 
the prevalence of  infection is as high as 90%, whereas 
in developed countries, excluding Japan, the prevalence 
is below 40%[1]. Diagnostic methods to detect H. pylori 
infection are diverse, and the choice of  one method or 
another depends on several factors, such as the avail-
ability of  diagnostic tests, need to perform an endoscopy, 
cost, accessibility, advantages and disadvantages of  each 
method, and age of  patients. 
Triple therapy is the standard treatment for H. pylori. 
Although triple therapy offers acceptable cure rates, qua-
druple therapies that use various combinations of  drugs, 
sequential therapies, and concomitant therapies have been 
introduced as effective alternatives for H. pylori treatment. 
In this paper, we review the main diagnostic methods for 
H. pylori infection, according to the principal priorities 
used by clinicians (i.e., initial diagnosis and confirmation 
of  eradication of  infection), and discuss the key factors 
related to treating H. pylori.
DIAGNOSIS OF INFECTION
Several methods are currently available to detect the pres-
ence of  H. pylori, each with its own advantages, disad-
vantages, and limitations. A classic way to categorize the 
methods is according to whether or not an endoscopy is 
necessary. Biopsy-based tests include histological evalu-
ation, culture, polymerase chain reaction (PCR), and the 
rapid urease test (RUT), all of  which are performed on 
tissue obtained during endoscopy. Alternatively, the urea 
breath test (UBT), serology, and stool antigen test (SAT) 
can be performed as non-invasive procedures. A second 
way to classify these tests is according to whether they 
are used before or after H. pylori eradication treatment. 
For the purposes of  this review, we will classify diagnos-
tic tests in this manner because this classification may be 
more useful to a clinician.
DIAGNOSTIC TESTS BEFORE 
TREATMENT OF H. PYLORI INFECTION
Invasive methods to detect H. pylori infection 
Histology: As the standard method to diagnose H. 
pylori infection, histological examination provides criti-
cal information related to the mucosa (e.g., presence and 
severity of  inflammation, intestinal metaplasia, glandular 
atrophy, dysplasia, and neoplasia). Several studies have 
recommended that both antrum and corpus biopsies be 
collected[2-5]. The gold standard for gastric biopsy collec-
tion is the updated Sydney classification system, which 
indicates sampling from 5 biopsy sites. One specimen 
each should be obtained from the lesser curvature of  the 
corpus about 4 cm proximal to the angulus (Ⅰ), from the 
lesser (Ⅱ) and greater curvature of  the antrum (Ⅲ), both 
within 2 to 3 cm of  the pylorus, from the middle portion 
of  the greater curvature of  the corpus, approximately 8 
cm from the cardia (Ⅳ), and from the incisura angularis 
(Ⅴ)[6]. Despite the recommendations, this approach for 
biopsy collection is scarcely used in daily practice because 
of  the large number of  biopsies suggested. Endoscopy is 
an uncomfortable and time-consuming procedure. How-
ever, the analysis of  fewer biopsy samples than recom-
mended can lead to an underestimation of  the presence 
of  H. pylori, sampling error, and false negatives. 
To detect H. pylori in biopsy samples, a routine hema-
toxylin and eosin (HE) stain is usually sufficient. When 
the results of  this stain are inconclusive, special stains, 
such as Warthin-Starry, Giemsa, toluidine blue, acridine 
orange, McMullen, Genta, Dieterle, and Romanouski 
stains, or immunochemical methods can be used. Present 
guidelines suggest that at least 2 different stain techniques 
be used on biopsied tissue: HE to evaluate inflamma-
tory cells, and Giemsa or Genta stain to detect H. pylori. 
Although the Genta stain is able to visualize both inflam-
matory cells and H. pylori by combining a silver stain, HE, 
and Alcian blue, it is technically complex. In contrast, 
the Giemsa stain is technically simple, highly sensitive, 
and inexpensive. Thus, the Giemsa stain is the preferred 
method in clinical practice. All other methods are used 
specifically for research proposes[7-10].
Histology has a few limitations. The tissue changes 
are assessed subjectively, which results in an interobserver 
variation in scoring for the evaluated parameters. Also, 
an endoscopy is needed to obtain the tissue samples for 
histology. Due to the patchy distribution of  H. pylori in 
the gastric mucosa, tissue specimens should be obtained 
from different areas of  the stomach. The sensitivity and 
specificity of  histology for H. pylori diagnosis vary from 
53% to 90%, depending on the pathologist’s experience 
and density of  colonization. Increasing the number of  
biopsies and employing specific stains can increase the 
sensitivity of  histology[11]. 
In a histological section, H. pylori appear as a curved 
or spiral bacillus on the epithelial surface, in the mucus 
layer, and within gastric glands. Other Helicobacter spe-
cies, such as Helicobacter heilmanii (H. heilmanii), are also 
detected in the human stomach. H. heilmanii, a zoonotic 
infection in humans that can be acquired from cats or 
dogs and can cause chronic gastritis, is present in about 
0.1% of  gastric biopsies. H. heilmanii is straight and much 
longer than H. pylori; thus, the two species can be easily 
distinguished[12]. 
Histopathologic studies are practiced less often in 
children because of  the need to perform an endoscopy. A 
recent study that included an analysis of  histopathologic 
lesions in 96 Brazilian children with H. pylori infection 
showed that H. pylori was identified in 51.8% of  chil-
dren[13]. Moderate to severe chronic active gastritis was 
present in the antrum (70.5%) and the corpus (45.2%), 
with more severe gastritis observed in the antrum than in 
the corpus (P < 0.05). The topographic distribution of  
inflammation was pangastritis (61.9%), followed by antral 
(32.1%) and corpus (5.9%). H. pylori density was higher in 
the antrum than in the corpus.
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Fluorescent in situ hybridization (FISH) is a new 
method used on histological preparations that allows 
detection of  a specific bacterial factor or feature, such 
as clarithromycin resistance, in addition to H. pylori[14,15]. 
FISH uses a set of  fluorescent protein-labeled oligo-
nucleotide probes that target a specific gene; common 
probes used are the 16S and 23S ribosomal RNA genes. 
It takes about 3 hours to perform this assay and probe 
for both for H. pylori and clarithromycin resistance. The 
ability to assess both probes in a short time adds value to 
the diagnosis of  H. pylori. In situ hybridization and immu-
nochemical methods have been used to detect the precise 
location of  the bacteria in the gastric mucosa[16]. Despite 
the advantages of  FISH is laborious, expensive, and not 
used in clinical practice.
Culture: A recently obtained gastric biopsy specimen 
is the ideal specimen for culturing H. pylori because no 
notable amount of  commensal bacterial flora is expected 
(except in patients with reduced gastric acid production, 
in whom an overabundance of  commensal bacteria is 
possible). Procedures that are less invasive than biopsy 
collection include gastric juice sampling or the string test. 
Specimens from gastric juice samples or the string test 
can also be used for culture; however, the sensitivity is 
lower than when biopsy specimens are used[17-19]. 
Culturing typically has a sensitivity greater than 90% 
and a specificity of  100% when performed under optimal 
conditions[20]. However, lower sensitivity values have been 
reported (85.4%) with a confirmed 100% specificity[21], 
and a culture sensitivity of  40.0% was reported in bleed-
ing patients[22]. In patients with atrophy, the sensitivity, 
specificity, positive predictive value (PPV), negative pre-
dictive value (NPV), and overall accuracy for culture were 
96%, 100%, 100%, 80%, and 97%, respectively[23]. In a 
pediatric population, sensitivity and specificity values of  
95.8% and 96.4%, respectively, have been reported[24]. 
H. pylori is very delicate and needs to be cultured as 
soon as possible after sampling. Biopsies can be kept in a 
transport medium (e.g., Stuart’s transport medium) for up 
to 24 h at 4 ℃. Once isolated, H. pylori can be stored fro-
zen at -80 ℃, preferably in broth with 15% to 20% glyc-
erol. Several types of  medium can be used for H. pylori 
culture, including selective agars (e.g., Pylori-agar, Skirrow 
agar, Wang media, and others), which contain specific an-
tibiotics to inhibit commensal bacteria, and nonselective 
agars (e.g., blood agar, Columbia blood agar, and others). 
Cultures should be incubated under microaerobic condi-
tions (85% N2, 10% CO2, 5% O2) at 35 to 37  ℃ for at 
least 7 d before discarding cultures as negative. Positive 
identification of  H. pylori is based on morphological char-
acteristics and positive catalase, oxidase, and urease reac-
tions[25].
Culturing is the most specific method for detecting 
H. pylori, although the results depend on the microbiolo-
gist’s experience, specimen quality, and use of  transport 
media[26]. For many years, the role of  culturing H. pylori 
to diagnose infection was limited to research and epide-
miologic studies. In clinical practice, culturing has mainly 
been used to confirm the antibiotic sensitivity of  H. pylori 
after 2 treatment failures in patients. It is generally not 
considered a routine diagnostic method and is not avail-
able in most medical institutions worldwide. Yet, given 
the increase in antibiotic resistance rates, especially to 
clarithromycin and metronidazole, it would be desirable 
for more laboratories to be able to perform the culture 
and susceptibility test before 2 treatment failures have oc-
curred. 
Considering the increasing failure rate of  standard 
therapies, bacterial culture may be an indispensable 
method for surveying antibiotic resistance in populations 
and managing antibiotic failure. A recent report described 
high antibiotic resistance rates in a pediatric population 
of  Brazilian children and adolescents[27]. This study ana-
lyzed 77 H. pylori clinical isolates obtained from patients 
without previous eradication treatment for H. pylori infec-
tion, and 6 strains from patients in whom previous eradi-
cation treatment had failed. The study reported a global 
resistance rate of  49.3%, with 40% of  strains resistant 
to metronidazole and 19.5% to clarithromycin. Another 
study of  61 H. pylori strains isolated from Japanese chil-
dren[28] found overall resistance rates against clarithromy-
cin, amoxicillin, and metronidazole of  36.1%, 0%, and 
14.8%, respectively. 
Polymerase chain reaction: PCR allows researchers 
and clinicians to identify H. pylori in small samples that 
have few bacteria present. It does not require any special 
processing supplies or transportation, and it can be per-
formed on samples obtained by both invasive and nonin-
vasive methods. Moreover, PCR can be performed faster 
than many other diagnostic methods, used to identify di-
verse bacterial genotypes, and employed in epidemiologi-
cal studies. A considerable drawback of  PCR is that it can 
detect DNA segments of  dead bacterium in the gastric 
mucosa of  patients after treatment; consequently, it can 
produce false-positive results[19,29,30]. Molecular detection 
of  H. pylori using PCR is possible in materials obtained 
by non- or minimally invasive procedures, such as gastric 
juice, gastric content, saliva, stools, etc. Thus, molecular 
methods can be easily applied to specimens obtained by 
string tests or orogastric brushes. Molecular testing may 
be of  particular value for samples that can no longer be 
successfully cultured because of  prolonged transport or 
in cases where isolation of  H. pylori is not feasible as a 
result of  contamination. 
In gastric biopsy specimens, molecular methods such 
as PCR have proved their worth in detecting pathogens 
and testing for clarithromycin resistance, which is attrib-
utable to mutations in the 23S rRNA gene[31]. Because of  
the increasing prevalence of  antibiotic resistance in some 
populations with a high prevalence of  H. pylori, molecular 
tests may have important implications as relevant alterna-
tives for H. pylori diagnosis. In other Gram-negative spe-
cies, efflux pumps have an important role in resistance 
to antibiotics, and options for treating some infections 
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office-based whole-blood tests nor antibody detection in 
urine or saliva show similar reliability to laboratory-based 
tests, and they are not recommended to diagnose H. pylori 
infection[38].
Serology tests are relatively cheap and readily avail-
able. Indeed, the accessibility of  these tests can result in 
their use by laboratories that are inexperienced in H. pylori 
diagnosis, which can result in misinterpretation of  the 
data. Another drawback is the prolonged existence of  an-
tibodies in the host even after eradication therapy[39]. As 
a result, there can be a considerable amount of  time be-
tween the administration of  eradication therapy and the 
confirmation of  a significant decline in antibody titers. 
This situation limits the utility of  serology in confirming 
the eradication of  infection. In contrast, serology results 
are not affected by recent antibiotic or PPI treatment. In 
general, the serology test is very good at correctly identi-
fying patients with a negative result[40] and is a good alter-
native to the UBT test. 
Serology has been used both for the detection of  
the whole bacterial cell and of  specific H. pylori proteins. 
Not all H. pylori-infected subjects develop disease, and 
the wide spectrum of  diseases associated with H. pylori 
infection may depend on the heterogeneity of  H. pylori 
strains[41]. Between-strain heterogeneity can be due to the 
presence or absence of  virulence factors, some of  which 
have been used as serological markers. These factors in-
clude the cagA and vacA genes, which have been linked to 
increased pathogenicity of  H. pylori. 
The cagA gene encodes a 120- to 140-kDa protein, 
CagA[42]. Strains expressing the CagA protein induce 
more severe inflammation, a higher degree of  gastric 
atrophy, and a higher incidence of  duodenal ulcer and 
gastric adenocarcinoma of  the intestinal type[43]. The 
vacA gene is present in all H. pylori strains; however, it is 
only expressed in 50% to 65% of  strains. The vacA gene 
encodes an 81- to 91-kDa protein, VacA, which provokes 
vacuole formation in gastric epithelial cells[42]. Both pro-
teins, CagA and VacA, are immunogenic, and serologic 
assays have been developed to diagnose H. pylori infec-
tion and the seroprevalence of  virulence factors[44-46]. Re-
cently, six highly immunogenic virulence factors, CagA, 
VacA, GroEL, gGT, HcpC, and UreA, were expressed 
in Escherichia coli, purified, and immobilized on nitrocel-
lulose membranes to detect serologic immune responses 
against these virulence factors in the patient’s sera. This 
new assay demonstrated sensitivity and specificity values 
of  97.6% and 96.2%, respectively[47].
TESTS USED TO DETECT THE 
ERADICATION OF INFECTION
Urea breath test
The UBT is based on the ability of  H. pylori, if  present in 
the gastric environment, to break down orally absorbed 
13C- or 14C-labeled urea into CO2 and ammonia. 13CO2 
or 14CO2 diffuses into the blood, is exhaled via the lungs, 
and can be measured in the exhaled air. The test is easy 
caused by multidrug-resistant bacteria are limited[32].
Rapid urease test: The RUT utilizes the ability of  H. 
pylori to produce large quantities of  urea as the basis for 
diagnosing infection. Biopsies obtained during endoscopy 
are placed in a medium containing urea and a pH indica-
tor. If  urease is present, the urea is broken down into 
carbon dioxide and ammonia, which increases the pH of  
the medium and causes a subsequent color change in the 
pH indicator. The RUT produces a result in a range of  
minutes up to 24 h, depending on the number of  bacteria 
in the biopsy. The RUT is inexpensive, rapid, widely avail-
able, and highly specific. 
Although some members of  the microbiota in the 
oropharynx produce urease that is swallowed in the sa-
liva, this weaker enzyme is denatured rapidly because of  
the high acidity of  the stomach. However, there is a high 
possibility of  false-negative results with RUT due to de-
creased urease activity, which could be caused by a recent 
intake of  antibiotics, bismuth compounds, or proton 
pump inhibitors (PPIs)[33]. A false-negative urease test can 
also be obtained in patients with achlorhydria. The RUT 
sensitivity is affected by the amount of  bacteria in the bi-
opsy; at least 10000 cells are required for a positive result. 
Low sensitivity and specificity of  the RUT have been 
reported in the presence of  blood. The RUT specificity 
decreases (and, thus, the risk of  a false positive increases) 
with increasing incubation time. When results from RUTs 
performed on individual gastric antrum and corpus tissue 
specimens and on combined specimens were compared 
to histology results (as the gold standard), combining the 
tissues increased H. pylori detection from 64% in separate 
specimens to 69.2%[34]. Commercial RUTs have specifici-
ties above 95% to 100%, but their sensitivity is slightly 
less (approximately 85%-95%). Commercially available 
RUTs include gel- (CLOtest, HpFast) and paper-based 
tests (PyloriTek, ProntoDry HpOne)[35,36].
Noninvasive methods to detect an infection
Serology: Several types of  tests have been used to iden-
tify antibodies against H. pylori. The enzyme immunoas-
say (EIA) test has been the most prevalently used. Most 
commercial EIA tests are based on detecting IgG, with 
sensitivity and specificity values ranging from 60% to 
100%. Critical factors important in evaluating the qual-
ity of  serology tests for the detection of  active H. pylori 
infection include the prevalence of  infection, variations 
in geography, and characteristics of  the study popula-
tions. Local validation of  a serology test is necessary, and 
it is imperative to make adjustments to cut-off  levels for 
specific populations. In general, tests containing complex 
antigen mixtures of  various strains show the highest sen-
sitivity[37].
Numerous characteristics should be considered when 
determining whether a serology test should be used as the 
method of  choice. In particular, a serology test should 
be considered in patients with a recent use of  antibiot-
ics or PPIs, bleeding ulcers, or gastric atrophy[38]. Neither 
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to perform and does not require endoscopy. 13C is a non-
radioactive innocuous isotope, and it can be safely used 
in children and women of  childbearing age. An isotope 
ratio mass spectrometer is generally used to measure 13C 
in breath samples; however, the machine is expensive[48]. 
In contrast, 14C-urea is inexpensive but requires the use 
of  a nuclear medicine department licensed for storage 
and disposal of  radioactive reagents[49,50]. 
The sensitivity and specificity of  the UBT exceed 
90% in most studies[51]. The excellent sensitivity of  the 
UBT, especially after eradication therapy, may be ex-
plained by the fact that the UBT is more likely to pro-
duce positive results than biopsy-based tests in cases of  
moderate colonization or patchy distribution of  H. pylori. 
False-positive results due to other urease-forming patho-
gens are rare. In contrast to serology, the UBT may pro-
duce false-negative results if  performed after the use of  
H. pylori- and urease-suppressive therapies, such as PPIs 
and antibiotics. Thus, if  the patient has recently ingested 
PPIs, antibiotics, or bismuth compounds, the UBT may 
have limited value[50]. Corpus-predominant gastritis can 
also produce false-negative 13C-UBT results. Misdiagnosis 
of  corpus-predominant gastritis could lead to a major 
misassessment of  patients that need endoscopy and/or 
eradication therapy[52].
Post-treatment UBT is usually performed 4 to 6 wk af-
ter eradication therapy[53]. A recent meta-analysis showed 
that the 13C-UBT assay was accurate across all ages. The 
authors demonstrated a sensitivity of  95.9%, specificity 
of  95.7%, Likelihood-ratio ratio (LR)+ 17.4, LR- 0.06, 
and diagnostic odds ratio (OR) of  424.9. The 13C-UBT 
had a high accuracy in children older than 6 years, with a 
sensitivity of  96.6%, specificity of  97.7%, LR+ 42.6, LR- 
0.04, and diagnostic OR of  1042.7. In this study, they ob-
served a greater variability in accuracy in children under 
6 years old, with the test demonstrating a sensitivity of  
95%, specificity of  93.5%, LR+ 11.7, LR- 0.12, and diag-
nostic OR of  224.8[54]. 
Stool antigen test
The SAT uses an enzyme immunoassay to detect the 
presence of  antigens against H. pylori in stool samples. 
It is a reliable method to diagnose an active infection 
and to confirm an effective treatment of  infection. Stool 
samples may be stored for 24 h at room temperature or 
72 h at 4 ℃. Without refrigeration, the SAT suffers a sig-
nificant reduction of  sensitivity within 2 to 3 d[55]. Results 
of  the SAT may be affected by disorders of  the digestive 
tract, PPI treatment, or the presence of  a bleeding ulcer.
The diagnostic accuracy of  the SAT in detecting 
eradication of  H. pylori infection has been evaluated. A 
recent study compared the ability of  2 SAT methods, 
the enzyme immunoassay (Premier Platinum HpSA) and 
immunochromatographic method (ImmunoCard HpSA 
STAT), to detect H. pylori after eradication therapy in dys-
peptic patients. The sensitivity, specificity, PPV, NPV, and 
accuracy were 100%, 91.0%, 84.6%, 100%, and 94.0%, 
respectively, for ImmunoCard HpSA STAT, and 84.9%, 
92.5%, 84.8%, 92.5%, and 90.0%, respectively, for Pre-
mier Platinum HpSA. Another study evaluated 5 SATs, 
including 2 monoclonal EIAs and 3 rapid immunochro-
matographic assay tests, for their ability to diagnose H. 
pylori infection in adult patients with dyspeptic symptoms 
before eradication therapy. For the 2 EIAs, the sensitiv-
ity and specificity were 92.2% and 94.4%, respectively, 
for the Premier Platinum HpSA Plus test, and 48.9% and 
88.9%, respectively, for the H. pylori antigen test. For the 
3 rapid immunochromatographic assays, the sensitivity 
and specificity were 86.7% and 88.9%, respectively, for 
the One Step HpSA test; 68.9% and 92.6%, respectively, 
for the ImmunoCard STAT HpSA test; and 78.9% and 
87%, respectively, for the H. pylori fecal antigen test. The 
Premier Platinum HpSA Plus EIA test was the most ac-
curate test to diagnose H. pylori infection in adult dyspep-
tic patients[56]. 
The sensitivity and specificity of  the SAT vary in dif-
ferent clinical settings, and whether the test is given pre- 
or post-treatment[57,58]. In untreated patients, detection of  
H. pylori infection by the SAT is comparable to the UBT. 
However, posteradication, especially in populations with 
low H. pylori prevalence, the performance of  the UBT is 
superior to the SAT. 
The first SAT introduced was the polyclonal SAT 
(Premier Platinum HpSA, Meridian Bioscience Inc., OH, 
United States). This test was followed by a monoclonal 
test (Femtolab H. pylori, Connex, Germany), which is 
better than the polyclonal test in both testing untreated 
patients and following up with treated patients[59-61]. 
The superiority of  the monoclonal SAT compared 
to the polyclonal test, both for early diagnosis of  infec-
tion and for validation of  H. pylori’s eradication following 
treatment, has been reported[57]. According to European 
Guidelines, the monoclonal test and UBT are the only 2 
noninvasive tests recommended for detecting the success 
or failure of  eradication treatment.
Detection of  H. pylori antigen in stool using a mono-
clonal enzyme-linked immunosorbent assay is one of  the 
most efficient non-invasive tests for diagnosis of  infec-
tion in children[62]. The H. pylori SAT seems to perform 
well in children, independent of  the child’s age[63-65]. An 
analysis of  20 studies of  the SAT in a total of  2789 pa-
tients before they received treatment for H. pylori revealed 
values for sensitivity, specificity, PPV, and NPV of  90%, 
96%, 93%, and 93%, respectively. In 8 studies examining 
a total of  307 children, encouraging results were achieved 
for the confirmation of  H. pylori eradication after therapy 
using the SAT, with a sensitivity of  97%, specificity of  
97%, PPV of  88%, and NPV of  99%[66].
TREATMENT OF H. PYLORI INFECTION
Since the discovery of  H. pylori in 1983, this Gram-
negative microaerophilic spiral bacillus has been studied 
extensively. It currently infects more than 50% of  the 
world’s population, and in the last decade, it has been 
recognized as a major human pathogen[67]. Today, the 
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involvement of  H. pylori in active chronic gastritis, its as-
sociation with gastroduodenal ulcer, and its well-accepted 
role as a risk factor for the development of  gastric cancer 
are well documented[68]. 
There are many schemes for treating H. pylori infec-
tion; however, an optimal treatment has not been de-
fined, and there is not a single antibiotic treatment that 
can eradicate it. Historically, a combination of  various 
antibiotics has been used to eradicate the infection. The 
antibiotics used include clarithromycin, amoxicillin, met-
ronidazole, tetracycline, fluoroquinolones, tinidazole, and 
others. These antibiotics are often used in combination 
with antisecretory agents, such as PPIs, or with bismuth 
salts. Various combinations of  these agents have shown 
to be effective with different efficacy rates of  eradication 
and tolerability.
The effectiveness of  the most commonly used thera-
pies has been increasingly compromised by the rapid 
emergence of  antibiotic-resistant strains of  H. pylori and 
by poor adherence to treatment by patients. These fac-
tors have reduced the effectiveness of  treatment to unac-
ceptable levels (≤ 80%) in many geographic areas. Con-
sequently, new treatment strategies have recently been 
validated and used to replace the standard triple therapy. 
These approaches have especially been used in areas with 
a high resistance to clarithromycin, which is a major risk 
factor for failure of  treatment regimens[69]. Resistance to 
amoxicillin has remained relatively stable, while resistance 
rates to metronidazole and clarithromycin have been 
steadily increasing[70-74]. The prevalence of  antibiotic re-
sistance varies considerably by region and is related to the 
use of  antibiotics, such as clarithromycin and metronida-
zole, for respiratory or gastrointestinal infections.
One of  the first strategies developed for the treat-
ment of  H. pylori infection was the test-and-treat strategy. 
This therapy is recommended for patients younger than 
45 years old that have persistent dyspepsia, peptic ulcer 
disease, low-grade MALT, and atrophic gastritis. The test-
and-treat strategy is based on determining the existence 
of  H. pylori and eradicating it when detected. An alterna-
tive to the test-and-treat strategy is desirable in dyspeptic 
patients that live in populations with a moderate-to-high 
prevalence of  H. pylori infection (≥ 10% to 20%), where-
as the empirical PPI strategy may be preferable in popu-
lations with a low prevalence of  H. pylori infection[75-77]. 
The test-and-treat strategy must be carefully used in 
populations with a low prevalence of  H. pylori because 
diagnostic tests are less accurate in these populations[78]. 
Only a small proportion of  patients that have functional 
dyspepsia experience long-term improvement in their 
symptoms after elimination of  H. pylori[79-81]. 
It is currently recommended to split first-line empiric 
therapy into two large groups: populations with low and 
with high resistance to clarithromycin. For these groups, 
the acceptable resistance levels are set as < 15% to 
20%[77]. The following information lists current recom-
mendations and therapies available for the eradication of  
H. pylori. They are mentioned as first-, second-, and third-
line treatments, according to clarithromycin resistance.
First-line treatment in areas with low clarithromycin 
resistance
The most frequently used strategy is triple therapy. This 
therapy is composed of  a PPI (lansoprazole 30 mg/12 
h, omeprazole 20 mg/12 h, pantoprazole 40 mg/12 h, 
rabeprazole 20 mg/12 h, or esomeprazole 40 mg/24 h), 
clarithromycin (500 mg/12 h), and amoxicillin (1 g/12 
h), taken for 7 to 14 d. The duration of  therapy is con-
troversial, although a meta-analysis suggested that 14 d 
provides eradication rates 5% higher than those for 7 d. 
In cases of  allergy to penicillin, metronidazole is an op-
tion to replace amoxicillin, as it is equally effective and 
considered equivalent[82].
There are several explanations for why clarithromy-
cin susceptibility reduces the success rate of  therapy. 
These explanations include a poor adherence to the drug 
regimen by the patient, gastric acidity, concentration 
of  bacterial strains, bacterial mutations, and resistance 
to clarithromycin. There is also significant variability in 
these numbers. For example, in the Netherlands, where 
resistance to clarithromycin is not prevalent, it is between 
1% and 5%[77].
The efficacy rates of  triple therapy have shown to de-
pend on PPIs; thus, various strategies, such as increasing 
the dose of  PPIs and increasing the length of  treatment, 
have been attempted to improve the success of  triple 
therapy. A meta-analysis demonstrated an increase in the 
eradication rate from 6% to 10% compared with standard 
doses of  PPI. The subanalysis specifically mentioned that 
a double dose of  esomeprazole showed a greater ben-
eficial effect. The presence of  various polymorphisms in 
the host’s metabolism can alter the effectiveness of  PPIs, 
since PPI function depends on the cytochrome (CYP) 
450 2C19 and MDR polymorphisms. A recent meta-anal-
ysis showed that hosts who are extensive PPI metaboliz-
ers (depending on CYP2C19 status) had lower cure rates. 
Furthermore, a lower cure rate was obtained with the 
MDR T/T genotype compared with the T/C and C/C 
genotypes[83].
In addition to the standard treatment for H. pylori 
infection, an adjuvant therapy is sometimes used. For 
example, lactoferrin has been used as adjuvant therapy. 
Two meta-analyses that examined the use of  lactofer-
rin showed a decrease in the adverse effects of  stan-
dard treatment[84,85], although the latest consensus of  
Maastricht (IV) mentions that more evidence and better 
designed studies are required[77] before definitive conclu-
sions can be drawn. Another adjuvant that has been used 
is Saccharomyces boulardii, and some studies have shown 
encouraging results[86]. 
First-line treatment in areas with high clarithromycin 
resistance
Quadruple therapy: In areas that have high resistance 
to clarithromycin, a quadruple therapy can be used. This 
therapy includes a combination of  a PPI, bismuth sub-
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salicylate (525 mg, × 4 daily), and 2 antibiotics, metroni-
dazole (250 mg × 4 daily) and tetracycline (500 mg, × 4 
daily), for 10 to 14 d. This regimen is well tolerated, and 
patients tend to adhere to the schedule; however, this 
therapy is not available in all areas. It is recommended 
that doctors have other alternatives in mind, such as se-
quential therapy or quadruple therapy without bismuth[77].
Sequential therapy: Sequential therapy was proposed by 
a group of  Italian researchers. It involves the combina-
tion of  a PPI and amoxicillin (1 g, × 2 daily) for 5 d, fol-
lowed by a PPI and tinidazole clarithromycin/metronida-
zole (500 mg, × 2 daily) for 5 d. Most studies have shown 
that sequential therapy and bismuth-based quadruple 
therapy have equivalent success in first-line therapy[82]. 
Sequential therapy was evaluated in a pediatric popula-
tion with iron deficiency[87]. Children aged 12 to 15 years 
with an active H. pylori infection were evaluated for se-
rum ferritin, and then were randomized into 2 groups to 
receive either standard or sequential eradication therapy. 
Six weeks after completing the therapy, eradication was 
detected by the UBT, and serum ferritin levels were mea-
sured. H. pylori eradication rates after either sequential 
or standard therapy were different; however, the serum 
ferritin levels were not significantly different between the 
two therapy groups or between the same group before 
and after treatment.
A recent meta-analysis evaluated H. pylori eradication 
rates in children after sequential therapy compared to 
triple therapy. This analysis included 857 children aged 3 
to 18 years who met the inclusion criteria. Of  the 409 pa-
tients who received sequential therapy, 318 (78%, 95%CI: 
73%-82%) were cleared of  the infection, compared with 
314 of  the 444 patients (71%, 95%CI: 66%-75%) who 
received standard triple therapy (RR = 1.14, 95%CI: 
1.06-1.23). The authors concluded that sequential therapy 
is superior to 7-d standard triple therapy, but is not sig-
nificantly better than 10- or 14-d triple therapy. Further-
more, they found no significant differences in the risk of  
adverse effects between groups that received different 
treatments.
Concomitant therapy: Concomitant therapy is used in-
stead of  sequential therapy in areas where the resistance 
to clarithromycin is greater than 20% and bismuth-based 
quadruple therapy is not available. Concomitant therapy 
involves the simultaneous administration of  3 antibiotics 
(metronidazole, clarithromycin, and amoxicillin) and a 
PPI for 10 d. This therapy is effective and well tolerated 
compared to conventional triple therapy[88].
A recent controlled trial compared concomitant 
therapy with triple therapy in Greece, where there is a 
high resistance to clarithromycin (25%) and metronida-
zole (40%). Concomitant therapy had an eradication rate 
of  90%, whereas triple therapy only had an eradication 
rate of  73.8%[89]. Unfortunately, the adverse effects of  
concomitant therapy were high, as 30.9% of  subjects re-
ported at least one adverse effect. However, the adverse 
effects were mild, and patients were able to complete 
their treatment despite them[90]. Another study analyzed 
a concomitant treatment with PPI, amoxicillin, rifabutin, 
and ciprofloxacin, and they observed H. pylori eradication 
rates of  95.2%. In patients with a penicillin allergy, the 
amoxicillin was replaced by bismuth with no significant 
effect on the eradication rate (94.2%)[91].
A clinical trial specifically compared concomitant and 
sequential therapies and found no difference in H. pylori 
eradication rates after treatment with these therapies. 
This clinical trial included H. pylori-infected patients from 
11 Spanish hospitals. Patients were randomized to re-
ceive either sequential or concomitant therapy. Sequential 
therapy included omeprazole (20 mg/12 h) and amoxicil-
lin (1 g/12 h) for 5 d, followed by 5 d of  omeprazole (20 
mg/12 h), clarithromycin (500 mg/12 h) and metronida-
zole (500 mg/12 h). Concomitant treatment included the 
same drugs, but the drugs were taken concomitantly for 
10 d. Four weeks after treatment ended, H. pylori eradi-
cation was confirmed with 13C-UBT or histology. The 
concomitant and sequential eradication rates were 87% 
and 81%, respectively, by intention-to-treat (P = 0.15) 
and 91% and 86%, respectively, per protocol (P = 0.131) 
They concluded that there was no significant advantage 
of  concomitant over sequential therapy[92]. 
A second study that compared sequential and con-
comitant therapies included 164 patients infected with 
H. pylori. Patients received either 14 d of  sequential (n 
= 86) or concomitant (n = 78) therapies. Patients in 
the sequential therapy group received rabeprazole (20 
mg) and amoxicillin (1 g) in the first week, followed by 
rabeprazole (20 mg), clarithromycin (500 mg), and met-
ronidazole (500 mg) in the second week. Patients in the 
concomitant therapy group received rabeprazole (20 mg), 
amoxicillin (1 g), clarithromycin (500 mg), and metroni-
dazole (500 mg) for 2 wk. Four weeks after completion 
of  treatment, H. pylori eradication was confirmed by 13C-
UBT. The intention-to-treat and per protocol eradication 
rates were 75.6% (95%CI: 66.3%-84.9%) and 76.8% 
(95%CI: 67.1%-85.5%) in the sequential therapy group, 
and 80.8% (95%CI: 71.8%-88.5%) and 81.3% (95%CI: 
71.6%-90.7%) in the concomitant therapy group, respec-
tively. The researchers concluded that the 2-wk concomi-
tant and sequential therapies showed suboptimal effica-
cies. Furthermore, in this study, there were no significant 
differences between the two therapies with regard to the 
eradication rates, compliance, or side effects.
Hybrid therapy: Hybrid therapy is a recently reported 
therapy that consists of  2 steps: (1) treatment with a PPI 
and amoxicillin (1 g/12 h) for 7 d, followed by (2) a PPI 
and 3 antibiotics, amoxicillin (1 g/12 h), metronidazole 
(500 mg/12 h), and clarithromycin (500 mg/12 h), for 7 
d. In a study comparing hybrid and sequential therapies, 
the eradication rates were 89.5% and 76.7% (P = 0.001), 
respectively. Similar severe adverse effects were observed 
in patients in both treatment groups. Specifically, 2.4% 
of  patients in the hybrid therapy group and 3.8% of  pa-
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tients in the sequential therapy group reported adverse 
effects[93]. 
A recent study included non-ulcer dyspepsia patients 
that were infected with H. pylori and compared concomi-
tant, sequential, and hybrid therapies[94]. Patients were 
randomized to receive one of  the following 3 treatments: 
(1) concomitant therapy with omeprazole (20 mg), amox-
icillin (1 g), clarithromycin (500 mg), and tinidazole (500 
mg) for 5 d; (2) sequential therapy with omeprazole (20 
mg) and amoxicillin (1 g) for 5 d, followed by omeprazole 
(20 mg), clarithromycin (500 mg), and tinidazole (500 
mg) for 5 d; or (3) hybrid therapy with omeprazole (20 
mg) and amoxicillin (1 g) for 7 d, followed by omeprazole 
(20 mg), amoxicillin (1 g), clarithromycin (500 mg), and 
tinidazole (500 mg) for 7 d. 13C-UBT was used to detect 
H. pylori eradication 6 wk after treatment. In this study, 
the intention-to-treat and per protocol analyses revealed 
eradication rates of  85.5% and 91.6%, respectively, with 
the concomitant therapy regimen; 91.1% and 92.1%, 
respectively, with the sequential therapy; and 80% and 
85.7%, respectively, with the hybrid therapy regimen. 
Second-line treatment in areas that have a low 
clarithromycin resistance
Options available in areas with a low resistance to clar-
ithromycin include bismuth-based quadruple therapy and 
therapies with a PPI and levofloxacin/amoxicillin[86,95]. 
However, levofloxacin use has been questioned, based 
on an increase in levofloxacin resistance[96]. Therefore, 
susceptibility studies should be performed before starting 
therapy.
Second-line treatment in areas that have high 
clarithromycin resistance
For the case in which bismuth-based quadruple therapy 
fails, a triple therapy containing a PPI, levofloxacin, and 
amoxicillin is recommended. Again, the increase in levo-
floxacin resistance should be taken into account[77].
Third-line treatment
After 2 failed treatments in areas that have either a low or 
high clarithromycin resistance, it is not advisable to pre-
scribe further antibiotic treatments. Whenever possible, 
biopsy specimens should be obtained to culture and test 
for susceptibility[81]. “Rescue” or “salvage” therapies have 
obtained good results in these cases. One rescue therapy 
is the use of  rifabutin (150 mg, × 2 daily), amoxicillin (1 
g, × 2 daily), and ciprofloxacin (500 mg, × 2 daily) for 14 
d. Although this therapy achieves an excellent response, 
severe adverse effects have been observed[97]. Other res-
cue therapies include a double dose of  PPIs plus azithro-
mycin (500 mg/d for 3 d), followed by a double dose of  
PPIs plus furazolidone (200 mg, × 3 daily) for 10 d in 
addition to a base therapy of  furazolidone (200 mg, × 2 
daily), bismuth subcitrate (120 mg, × 4 daily), and tetra-
cycline (500 mg, × 4 daily) in combination with a PPI at 
the doses described. For this treatment, the rate of  recur-
rence of  H. pylori infection after a successful eradication 
has been estimated at 11.5%[90]. 
Eradication of H. pylori in pregnancy
If  a patient is diagnosed with peptic ulcer during preg-
nancy or lactation, the condition should be managed only 
with acid suppression. Eradication of  H. pylori should 
be completed after childbirth. Bismuth, quinolones, and 
tetracyclines are contraindicated in pregnancy, and metro-
nidazole should be avoided[89]. 
To our knowledge, only one published report has 
examined eradication of  H. pylori in pregnant women, 
specifically in pregnant women with iron deficiency ane-
mia[98]. The researchers performed a randomized placebo-
controlled trial on 40 women that were between 14 and 
30 wk of  gestation and had H. pylori infection detected by 
the SAT. Women were randomly divided into 2 groups: 
group Ⅰ (n = 20) was treated with amoxicillin, clarithro-
mycin, and omeprazole for 2 wk, and group Ⅱ (n = 20) 
was treated with placebo. Both groups received therapeu-
tic doses of  iron and folic acid. After 6 wk of  therapeutic 
iron and folic acid supplementation, the rise in hemoglo-
bin, packed cell volume, serum iron, and percentage of  
transferrin saturation were significantly greater (P < 0.05) 
in the group given H. pylori eradication therapy compared 
to the placebo group. The authors concluded that there 
is a high prevalence of  H. pylori infection in pregnant 
women with iron deficiency anemia, and that eradication 
therapy resulted in a significantly better response to oral 
iron supplementation among H. pylori-infected pregnant 
women with iron deficiency anemia.
Use of probiotics in treating H. pylori infection
It has been suggested that probiotics compete directly 
with H. pylori by interfering with H. pylori adherence or by 
producing antimicrobial molecules. The efficacy of  Lac-
tobacillus reuteri (L. reuteri) in H. pylori eradication therapy 
has been investigated. In this study, H. pylori infection 
was identified by gastric histopathology and 13C-UBT. 
Intervention consisted of  108 colony-forming units of  
L. reuteri (DSM 17938) plus pantoprazole (20 mg, × 2 
daily) for 8 wk. Patients were examined 4 to 6 wk after 
therapy for H. pylori eradication by 13C-UBT. They found 
that L. reuteri plus pantoprazole twice daily cured 13.6% 
(3/22; 95%CI: 2.9%-34.9%) of  patients with H. pylori 
infection by intention-to-treat analysis and 14.2% (3/21; 
95%CI: 3.0%-36%) by per protocol analysis. Researchers 
concluded that L. reuteri might have a potential role in H. 
pylori eradication therapy, if  the cure rate can be improved 
by changes in dose, dosing interval, or duration of  thera-
py[77].
A recent meta-analysis investigated whether a prepa-
ration of  a Lactobacillus- and Bifidobacterium-containing 
probiotic could improve H. pylori eradication rates and 
reduce side effects[99]. The study included 10 clinical tri-
als and 1469 patients, with 708 patients in the probiotic 
supplementation group and 761 patients in the control 
group. Pooled ORs by intention-to-treat and per-protocol 
analyses in the probiotic supplementation group vs the 
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control group were 2.066 (95%CI: 1.398-3.055) and 2.321 
(95%CI: 1.715-3.142), respectively. The pooled OR of  the 
incidence of  total side effects was significantly decreased 
in the group that received probiotics supplementation 
(OR = 0.305; 95%CI: 0.117-0.793). They concluded that 
combining a Lactobacillus- and Bifidobacterium-containing 
probiotic with initial H. pylori eradication therapy in adults 
may have beneficial effects on the eradication rate and 
incidence of  total side effects.
Another study aimed to determine whether add-
ing probiotics to a standard anti-H. pylori regimen could 
minimize the prevalence of  gastrointestinal side effects 
and improve the eradication rate. In a double-blind, ran-
domized, placebo-controlled study, 66 H. pylori-positive 
children, diagnosed by RUT or histology, were treated 
with a triple drug treatment protocol (omeprazole, 
amoxicillin, and furazolidon) and randomly allocated to 
receive either a probiotic or a placebo[100]. All patients un-
derwent esophagogastroduodendoscopy. H. pylori status 
was assessed by the SAT 4 to 8 wk after completion of  
treatment. The H. pylori eradication rate was significantly 
higher in the group that received probiotics (P = 0.04). 
Furthermore, during treatment, there was a lower rate of  
nausea/vomiting (P = 0.02) and diarrhea (P = 0.039) in 
the probiotic-supplemented children than in the placebo-
treated children. The authors concluded that probiotics 
have a positive effect on the eradication of  H. pylori infec-
tion and the side effects of  H. pylori treatment. 
CONCLUSION
Infection by H. pylori remains the most frequent and per-
sistent bacterial infection worldwide; therefore, accurate 
diagnosis of  infection is imperative. There are several 
alternatives for diagnosis of  infection and detection of  
eradication after treatment for H. pylori infection. Ad-
ditionally, there are several therapies used for treatment. 
Determining the diagnostic method and therapies to use 
for each patient depends on several factors, such as the 
clinical condition of  the patient, the prevalence of  infec-
tion, and the prevalence of  clarithromycin resistance, 
among others.
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